These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23893036)

  • 1. Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience.
    Maneiro JR; Perez-Pampin E; Salgado E; Carmona L; Gomez-Reino JJ
    Rheumatol Int; 2014 Aug; 34(8):1059-63. PubMed ID: 23893036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
    Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
    Iannone F; Ferraccioli G; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Gorla R; Bazzani C; Govoni M; Farina I; Gremese E; Carletto A; Giollo A; Galeazzi M; Foti R; Bianchino L; La Grasta L; Lapadula G
    Clin Rheumatol; 2018 Feb; 37(2):315-321. PubMed ID: 28980085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological Dose Tapering in Daily Clinical Practice: A 10 Year Follow-up Study.
    Alperi-López M; Alonso-Castro S; Morante-Bolado I; Queiro-Silva R; Riestra-Noriega JL; Arboleya L; Ballina-García FJ
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):319-323. PubMed ID: 30318269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK; Choe JY; Park SH; Lee H
    Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.
    Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Li T; Aranda R; Becker JC; Lin C; Cornet PL; Dougados M
    Ann Rheum Dis; 2008 Aug; 67(8):1096-103. PubMed ID: 18055472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(®) as Biological Intensive Treatment for RA (ORBIT) study.
    Tanaka Y; Kubo S; Yamanaka H; Amano K; Hirata S; Tanaka E; Nagasawa H; Yasuoka H; Takeuchi T
    Mod Rheumatol; 2014 Sep; 24(5):754-62. PubMed ID: 25036232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
    Kizaki K; Yamashita F; Hayashi T; Funakoshi N
    Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis.
    Guyot P; Taylor P; Christensen R; Pericleous L; Poncet C; Lebmeier M; Drost P; Bergman G
    Arthritis Res Ther; 2011; 13(6):R204. PubMed ID: 22151924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.
    Feuchtenberger M; Kleinert S; Scharbatke EC; Gnann H; Behrens F; Wittig BM; Greger G; Tony HP
    Clin Exp Rheumatol; 2015; 33(3):321-9. PubMed ID: 25897681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.
    Horák P; Skácelová M; Hejduk K; Smržová A; Pavelka K
    Clin Rheumatol; 2013 Oct; 32(10):1451-8. PubMed ID: 23728498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
    Das S; Vital EM; Horton S; Bryer D; El-Sherbiny Y; Rawstron AC; Ponchel F; Emery P; Buch MH
    Ann Rheum Dis; 2014 May; 73(5):909-12. PubMed ID: 24385201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre.
    Addimanda O; Possemato N; Macchioni P; Salvarani C
    Clin Exp Rheumatol; 2014; 32(4):460-4. PubMed ID: 24960220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization.
    Emery P; Solem C; Majer I; Cappelleri JC; Tarallo M
    Rheumatol Int; 2015 Nov; 35(11):1837-49. PubMed ID: 26164150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.
    Petro AD; Dougherty J; England BR; Sayles H; Duryee MJ; Hunter CD; Kremer JM; Pappas DA; Robinson WH; Curtis JR; Thiele GM; Mikuls TR
    Int Immunopharmacol; 2021 Feb; 91():107260. PubMed ID: 33360371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.
    Westhovens R; Robles M; Ximenes AC; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Murthy B
    Ann Rheum Dis; 2015 Mar; 74(3):564-8. PubMed ID: 25550337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.
    Zhang J; Xie F; Yun H; Chen L; Muntner P; Levitan EB; Safford MM; Kent ST; Osterman MT; Lewis JD; Saag K; Singh JA; Curtis JR
    Ann Rheum Dis; 2016 Oct; 75(10):1813-8. PubMed ID: 26792814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.